Microsoft, weight loss drug sales, and GSK profits surge


In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Estonia’s weekend warriors: The ‘SAS’ civilians urging Brits to learn how to fight
Greece becomes first Orthodox Christian country to legalise same-sex marriage
Minnesota wins Wild matinee, tops Canucks 10-7
Home Office launches investigation after baby’s birth certificate ‘had Israel scribbled out’
Nintendo shares fall nearly 6% after report that the Switch 2 will be delayed until 2025